secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K/A
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001493152-24-016797
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt
-----------------------------------------------------------------------

- Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.
- Cash of $1.05M as of Dec 31, 2023; management cites substantial doubt about going concern.
- Convertible promissory notes total $94.9M, with $80.7M current; fair value change of $50.4M recorded as loss.
- Total operating expenses $8.8M (R&D $4.4M, G&A $4.4M), down from $13.7M in 2022.
- Business combination with Semper Paratus closed Feb 14, 2024; post-merger financing included $2M Series A and $1.2M Series A-1 preferred.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/0001493152-24-016797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-016797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer